跳到正文
Brand AI

CVS健康

争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 6 条

  1. 2026

    公开质疑CVS Health公司内部人士是否违反对股东的受托责任

    问题披露

    PR Newswire发布的一篇标题为"CVS Health公司内部人士是否违反了对股东的受托责任？"的文章，公开提出CVS Health公司内部人士是否违反其对股东应尽的受托责任的疑问。所提供材料仅包含标题，未说明提出质疑的一方、所指的具体行为，也未给出任何认定、结论或裁定。现有文本中未报告任何监管或司法结果。该条目日期为2026年9月26日，来源标注为PR Newswire发布。由于没有更多细节，本条目仅记录：围绕CVS Health内部人士及其对股东的受托责任，相关疑问曾被公开提出。

    来源

  2. 2026

    肯塔基大学起诉 CVS Health

    提起诉讼

    肯塔基大学在联邦法院起诉 CVS Health Corporation，指控其民事敲诈勒索、欺诈和违约。该大学称，该公司在五年间挪用了约 4,100 万美元的 340B 处方药收入。该大学依据《反敲诈勒索及腐败组织法》寻求赔偿。

    品牌回应

    • 否认 — CVS Health

      CVS refuted the charges in the lawsuit in a statement, saying, “We do not believe there is merit to these claims and we intend to vigorously defend the matter in court.

    • 否认 — CVS Health

      CVS Health spokesman Mike DeAngelis said the claims have no merit and the company plans to “vigorously defend the matter in court.”

    来源摘录

    • The suit, which was filed on Tuesday, accuses CVS and its subsidiary companies of civil racketeering, fraud and breach of contract.
    • UK is asking for damages under the RICO Act.
    • The university claims in the suit that the company diverted around $41 million in 340B prescription revenue that was supposed to go to its pharmacies over a five-year period, according to the Herald-Leader.
    来源

  3. 2022

    佛罗里达州与CVS Health及制药公司达成阿片类药物和解

    和解

    佛罗里达州与CVS Health、Teva Pharmaceutical Industries、Allergan及Endo International达成总额超过8.78亿美元的和解，处理有关这些公司助长该州阿片类药物危机的指控。公司在同意和解时否认有不当行为。

    当事方说明的目的. 解决相关索赔并避免下个月开庭审理。

    品牌回应

    • 否认 — CVS Health Corp, Teva Pharmaceutical Industries Ltd, Abbvie Inc's Allergan unit, and Endo International Plc

      The four companies denied wrongdoing in agreeing to settle.

    来源摘录

    • The four companies denied wrongdoing in agreeing to settle.
    • Florida has reached more than $878 million in settlements with CVS Health Corp and three drug companies to resolve claims and avert a trial next month over their roles in fueling an opioid epidemic in the third most populous U.S. state.
    来源

  4. 2021

    阿片类药物危机责任认定

    联邦陪审团认定CVS、Walgreens和Walmart在俄亥俄州两个县对阿片类药物危机负有实质性责任。该认定构成了关于药房配药实践和处方阿片类药物对公共健康影响的广泛诉讼的一部分。

    来源

  5. 2019

    CVS健康争议：CVS暂停销售Zantac及雷尼替丁产品

    整改

    CVS Pharmacy表示，在FDA警告雷尼替丁产品可能含有潜在人类致癌物后，暂停销售Zantac品牌和CVS Health品牌的雷尼替丁产品，暂停时间另行通知。报道指出，这些产品当时并未被召回，FDA也未建议患者停止服用。

    来源摘录

    • CVS Pharmacy announced Saturday that it has suspended the sale of all Zantac brand and CVS Health-brand ranitidine products until further notice
    • The announcement comes in response to an alert from the FDA that ranitidine products may contain a possible human carcinogen and cause cancer.
    • While Zantac and ranitidine products have not been recalled, and the FDA is not recommending patients stop taking these products, customers can still return the products to CVS for a refund.
    来源

  6. 1990

    Caremark健康和Medicare欺诈案件

    Caremark后来成为CVS Caremark结构的一部分，在1980年代末和1990年代初面临健康欺诈和Medicare欺诈争议。参考材料指出，与美国政府的相关和解总额超过2.5亿美元。

    来源